Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00322153 · ClinicalTrials.gov registry record · Phase 3
A Study of the Safety and Efficacy of Memantine in Moderate to Severe Alzheimer's Disease
A Phase 3 study, sponsored by Forest Laboratories.
- Completed
- Registry status
- Phase 3
- Development phase
- 677
- Enrollment target
NCT00322153 is a Phase 3 study that has completed, run by Forest Laboratories. The registered enrollment target is 677 participants.
The verdict
NCT00322153, a Phase 3 study, has completed, sponsored by Forest Laboratories.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 677 participants
- Enrollment target
Study Summary
The objective of this study is to evaluate the safety, tolerability, and efficacy of memantine compared to placebo in outpatients diagnosed with moderate-to-severe dementia of the Alzheimer's type on a concurrent acetylcholinesterase inhibitor (AChEI).
Interventions
- DRUG Placebo
- DRUG memantine ER
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 677 participants |
| Start Date | 2005-06 |
| Est. Completion | 2008-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00322153
The ClinicalTrials.gov registry entry for NCT00322153 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 677 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Forest Laboratories, which has 145 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00322153 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00322153 about?
NCT00322153 is a clinical study titled "A Study of the Safety and Efficacy of Memantine in Moderate to Severe Alzheimer's Disease". The objective of this study is to evaluate the safety, tolerability, and efficacy of memantine compared to placebo in outpatients diagnosed with moderate-to-severe dementia of the Alzheimer's type on a concurrent acetylcholinesterase inhibitor (AChEI).
What is the current status of trial NCT00322153?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 677 participants. The study started on 2005-06. Estimated completion is 2008-01.
What interventions are being tested in trial NCT00322153?
The interventions under investigation include: Placebo (DRUG), memantine ER (DRUG).
Who is sponsoring clinical trial NCT00322153?
This trial is sponsored by Forest Laboratories, which has 145 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.